Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Cannabidiol 100 MG/ML [Epidiolex]
DRUG
2 trials
Sponsors
Brigham and Women's Hospital
, DSM Nutritional Products, Inc.
Conditions
CBD Pharmacokinetics
Healthy Participants
Opioid-use Disorder
Phase 1
A Pharmacokinetic Study to Compare CBD-NE to Epidyolex in Healthy Adult Volunteers Under Both Fed and Fasted Conditions
Completed
NCT06578455
DSM Nutritional Products, Inc.
CBD Pharmacokinetics, Healthy Participants
Start: 2024-08-30
End: 2024-12-16
Updated: 2024-12-17
Phase 2
Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder
Completed
NCT04982029
Brigham and Women's Hospital
Opioid-use Disorder
Start: 2022-04-14
End: 2022-12-02
Updated: 2023-10-05
Related Papers
Comparative Pharmacokinetics and Safety of Cannabidiol in a Powder Formulation, CBtru<sup>®</sup>, vs an Oil-Based Formulation, Epidyolex<sup>®</sup>, Under Fasted and Fed Conditions in Healthy Participants: A Randomized Open-Label Cross-Over Phase I Study.
2026-03-26
Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: A pilot, double-blind, placebo-controlled, randomized cross-over trial
Frontiers in Psychiatry
2023-03-30
9 citations